WO2024059569A3 - Composition et méthode de rétrovirus pseudotypés universels - Google Patents

Composition et méthode de rétrovirus pseudotypés universels Download PDF

Info

Publication number
WO2024059569A3
WO2024059569A3 PCT/US2023/073983 US2023073983W WO2024059569A3 WO 2024059569 A3 WO2024059569 A3 WO 2024059569A3 US 2023073983 W US2023073983 W US 2023073983W WO 2024059569 A3 WO2024059569 A3 WO 2024059569A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
universal
retroviruses
composition
binding domain
Prior art date
Application number
PCT/US2023/073983
Other languages
English (en)
Other versions
WO2024059569A2 (fr
Inventor
Lei S. QI
Michael Chavez
Paul B. FINN
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of WO2024059569A2 publication Critical patent/WO2024059569A2/fr
Publication of WO2024059569A3 publication Critical patent/WO2024059569A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des systèmes de vecteurs rétroviraux utiles pour produire des rétrovirus pseudotypés universels pour des thérapies cellulaires et géniques. Les systèmes vectoriels comprennent un plasmide d'enveloppe et un plasmide d'encapsidation, au moins l'un de ces plasmides codant pour une fraction de liaison qui se lie directement à une cellule cible par l'intermédiaire d'un domaine de liaison cellulaire, ou qui se lie indirectement à une cellule cible par l'intermédiaire d'un domaine de liaison d'anticorps. L'invention concerne également des cellules d'encapsidation de rétrovirus associées, des rétrovirus, des particules de type viral, ainsi que des procédés pour leur production et des méthodes pour leur utilisation dans la prévention ou le traitement d'une maladie.
PCT/US2023/073983 2022-09-12 2023-09-12 Composition et méthode de rétrovirus pseudotypés universels WO2024059569A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263405720P 2022-09-12 2022-09-12
US63/405,720 2022-09-12

Publications (2)

Publication Number Publication Date
WO2024059569A2 WO2024059569A2 (fr) 2024-03-21
WO2024059569A3 true WO2024059569A3 (fr) 2024-05-02

Family

ID=90275878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/073983 WO2024059569A2 (fr) 2022-09-12 2023-09-12 Composition et méthode de rétrovirus pseudotypés universels

Country Status (1)

Country Link
WO (1) WO2024059569A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130315872A1 (en) * 2010-11-26 2013-11-28 Japan Science And Technology Agency Neuron-specific retrograde transport vector
WO2022183072A1 (fr) * 2021-02-26 2022-09-01 Kelonia Therapeutics, Inc. Vecteurs lentiviraux ciblant les lymphocytes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130315872A1 (en) * 2010-11-26 2013-11-28 Japan Science And Technology Agency Neuron-specific retrograde transport vector
WO2022183072A1 (fr) * 2021-02-26 2022-09-01 Kelonia Therapeutics, Inc. Vecteurs lentiviraux ciblant les lymphocytes

Also Published As

Publication number Publication date
WO2024059569A2 (fr) 2024-03-21

Similar Documents

Publication Publication Date Title
Scourfield et al. Growing functions of the ESCRT machinery in cell biology and viral replication
Zaitseva et al. HIV-1 exploits importin 7 to maximize nuclear import of its DNA genome
US6333195B1 (en) Crossless retroviral vectors
Reiser Production and concentration of pseudotyped HIV-1-based gene transfer vectors
EP0871459B1 (fr) Vecteur et procede permettant d'alimenter en acide nucleique des cellules non divisant
DE69830798T2 (de) Retrovirale vektoren, die funktionelle spleiss-donor- und spleiss-akzeptor-stellen enthalten
US7311907B2 (en) Lentiviral packaging cells
SA518391623B1 (ar) سلالات خلية مستقرة للإنتاج الفيروسي الرجعي
Indraccolo et al. Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors
Coeytaux et al. The cationic amphipathic α-helix of HIV-1 viral protein r (Vpr) binds to nucleic acids, permeabilizes membranes, and efficiently transfects cells
WO2008140579A3 (fr) Induction d'anticorps neutralisants largement réactifs par la concentration de la réponse immunitaire sur les épitopes v3 de l'enveloppe gp120 du vih-1
DE69033006T2 (de) Herstellungsverfahren für ein plasmid mit fähigkeiten zu expression und prozessierung nach translation eines retroviralen gens, so erhaltenes plasmid und dessen expressionsprodukt
WO2024059569A3 (fr) Composition et méthode de rétrovirus pseudotypés universels
DE60121572T2 (de) Synthetische gene für gagpol und deren verwendungen
DE19752855C2 (de) Retrovirale Pseudotyp-Vektoren mit modifizierten Oberflächen-Hüllproteinen und Verpackungszelle zu ihrer Herstellung für den selektiven Gentransfer
DE19639103A1 (de) Nukleinsäurekonstrukte mit Hybridpromotoren für gentherapeutische Maßnahmen
JP2023554504A (ja) プログラム可能なトランスポザーゼおよびその使用
WO2019145796A3 (fr) Vecteurs viraux encapsulés dans un polymère destinés à la thérapie génique
WO2005038035A2 (fr) Procedes de production et d'utilisation de retrovirus pseudotypes in vivo
EP1841878B1 (fr) Procede de generation de lignees cellulaires productrices de virus, et lignees cellulaires
JP6324892B2 (ja) Ｈｉｖ−１に対する革新的ワクチンとしての非組み込み型キメラレンチウイルスゲノム
Allison et al. The lower electronic states of MoN
Clark et al. A Mason-Pfizer Monkey virus Gag-GFP fusion vector allows visualization of capsid transport in live cells and demonstrates a role for microtubules
EP1216299A2 (fr) Transfert de genes dans des lymphocytes humains au moyen de vecteurs retroviraux a ciblage cellulaire scfc
DE69937556T2 (de) Amphotrope retrovirus-verpackungszelllinie, verfahren zur herstellung und verwendung

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23866393

Country of ref document: EP

Kind code of ref document: A2